A Pilot Study of Recombinant Human Relaxin (rhRlx) in Compensated Congestive Heart Failure
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This trial is a single center, open-label, dose-finding study of recombinant human relaxin
(rhRlx) given intravenously (IV) to patients with stable, compensated CHF.
Phase:
Phase 2
Details
Lead Sponsor:
Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies